Pfizer continues its deal spree with a $600M option pact to buy AM-Pharma

John Carroll

Continuing a aimed at beefing up a weak pipeline, has agreed to pay $ 87.5 million for a stake in the Dutch biotech AM-Pharma along with an to buy the biotech. And there's another $ 512.5 million on the table should exercise its option, with the deal hinging on the biotech's successful completion of a Phase II study of a new treatment for acute kidney injury (AKI) related to sepsis.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS